Gilead Sciences Inc.
Gilead Announces Q1 2024 Financial Results and Strategic Updates
Summary
Gilead Sciences announced its Q1 2024 financial results, highlighting a 5% increase in total revenue to $6.7 billion, driven by growth in HIV, Oncology, and Liver Disease product sales. Despite the revenue growth, Gilead reported a net loss of $4.17 billion due to significant charges related to the acquisition of CymaBay Therapeutics, including a $3.9 billion IPR&D charge and a $2.4 billion IPR&D impairment. Non-GAAP diluted EPS was $(1.32) compared to $1.37 in the same period in 2023. Gilead also provided guidance for the full year 2024, with expectations for total product sales between $27.1 billion and $27.5 billion.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement